MedTrace Logo

Thorough QT Study of Nelfinavir

NCT00312182 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2009-04-10

No results posted yet for this study

Summary

To assess if nelfinavir has any clinically meaninful effect on cardiac function, namely ECG evaluation

Conditions

  • Healthy Volunteers

Interventions

DRUG

Nelfinavir

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-03-31
Completion
2006-06-30

Countries

  • United States
  • Belgium
  • Singapore

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00312182 on ClinicalTrials.gov